H2020Individual fellowship2017–2020

EXO-EYE · Stem Cell-Derived Exosomes for the treatment of Traumatic and Degenerative Eye Disease

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2017-06-01 → 2020-05-31
EU contribution
€269,858
Participants
2
Scheme
MSCA-IF

Lines connect the coordinator with its partners.

Results in brief

Stem Cell-Derived Exosomes for the treatment of Traumatic and Degenerative Eye Disease

Retinal ganglion cells (RGC) are the sole projection neuron of the retina and their axons make up the optic nerve. Damage to the optic nerve can come in many forms including neurodegenerative diseases like glaucoma, (affecting >7M EU citizens and increasing each year), as well as traumatic neuropathy. Traumatic injury affecting the optic nerve similarly leads to the death of RGC and blindness with an estimated 1-5% of head injuries resulting in optic nerve damage. The functional deficit and lack of recovery is because RGC and their axons are part of the central nervous system (CNS) and thus suffer from two unfortunate characteristics, they are irreplaceable, and their axons are incapable of regeneration. Current research and ongoing clinical trials suggests mesenchymal stem cells (MSC), such as those isolated from bone marrow, are an effective treatment for injured RGC, despite the mechanisms being poorly understood. MSC are a self-replicating multipotent stromal cell isolated from mesenchymal tissues. I and others have demonstrated the therapeutic efficacy of MSC in models of traumatic neuropathy and glaucoma, in vitro and in vivo. In retinal cultures, MSC proved neuroprotective and neuritogenic for injured RGC. After ONC, MSC transplanted into the vitreous were able to promote significant neuroprotection of RGC and regeneration of their axons. In animal models of glaucoma, MSC promote the survival of RGC and their axons and preserve their function. Although the efficacy is well established, the mechanisms by which MSCs protect RGC and promote regeneration of their axons is poorly understood, although strongly believed to be paracrine-mediated (through the secretion of factors). Mounting evidence exists for the potential of MSC to benefit nearby injured tissues through the secretion of exosomes. Exosomes are endocytic-derived structures composed of proteins, lipids and mRNA surrounded by a phospholipid bi-layer that are secreted into the extracellular space. Exosomes contain (along with proteins) mRNA and miRNA, which are both functional and, when delivered to another cell via fusion with the cell membrane, lead to the translation of new proteins or miRNA-mediated knockdown of genes. Various studies have shown that the protective effect MSC provide is indeed exosome-mediated. Currently MSC exosomes remain untested in the eye and exosomes in general have not been tested as a treatment for injured RGC. Equally their mechanism of action as a whole is poorly understood with very few miRNA candidates identified as the active components. The global aim of this project is to utilize exosomes from various sources and under different isolation techniques to promote survival of RGC and regeneration of their axons.

Data: CORDIS, © European Union

Project objective

The death and dysfunction of retinal ganglion cells (RGC) is a major cause of blindness in traumatic and degenerative ocular disease. For example, 60M people are affected by glaucoma with 4.5M becoming blind in both eyes, whilst optic neuritis affects 5/100,000 people and represents a significant problem for sufferers. RGC are the sole projection neurons and their axons make up the optic nerve, making them exquisitely sensitive to injury. As CNS neurons are irreplaceable, neuroprotective strategies are paramount to therapies aimed at preserving vision but as of yet, no such therapy exists. Current research has demonstrated significant neuroprotection by mesenchymal stem cells (MSC) including those from the bone marrow (BMSC), acting not as replacements for RGC but rather, as paracrine-mediated support cells. Clinical trials are already ongoing to test their efficacy in patients. Despite this, the exact mechanism behind their neuroprotective potential is not well understood. Recent studies have shown that exosomes, extracellular vesicles containing proteins, mRNA and miRNA may mediate much of the paracrine support offered by MSC and thus act as an easily purifiable cell-free alternative therapy for RGC neuroprotection. This proposal aims to assess the therapeutic efficacy of BMSC-derived exosomes, their characterisation and that of their RNA cargo. We will test these exosomes in animal models of traumatic (optic nerve crush) and degenerative (glaucoma) eye disease. Specifically, this proposal employs a novel strategy to promote RGC survival (relevant to ONC and glaucoma) and axon regeneration (relevant to optic nerve crush) through the use of exosomal delivery of mRNA/miRNA into injured RGC utilizing in vitro and in vivo injury models, RNAseq and CRISPR technology.

Original text from CORDIS.

Participants

  • THE UNIVERSITY OF BIRMINGHAM · BirminghamCoordinatorUnited Kingdom
  • United States Department of Health and Human Services · Washington D.C.United States

Links

Data: CORDIS, © European Union